Zachariah Holmes, PhD

Zachariah Holmes, PhD, is an associate in Goodwin’s Intellectual Property Litigation practice. He represents life sciences and biotechnology clients in complex patent and trade secret disputes, with a particular focus on biologics, peptide therapeutics, RNA-based technologies, and advanced therapeutic platforms. Zachariah’s practice spans district court litigation, inter partes review proceedings, ITC investigations, and arbitrations, and he regularly works on matters involving biosimilars, generic small molecule drugs, and pharmaceutical licensing disputes. Leveraging his scientific training in biochemistry and RNA biology, Zachariah helps litigation teams translate complex technical issues into strategic advocacy and practical business-focused litigation strategy.

Zachariah has supported litigation teams in high-stakes patent and trade secret disputes involving biologics, peptide therapeutics, and pharmaceutical formulations. His experience includes discovery, pretrial proceedings, and participation in federal jury trials. Some of his engagements include:

• Amyndas Pharmaceuticals Single Member P.C. et al. v. Alexion Pharmaceuticals, Inc. et al., C.A. No. 20-12254-LTS (D. Mass.). Representing Zealand Pharma A/S and Zealand Pharma U.S. Inc. in trade secret litigation related to peptide therapeutics
• Teva Pharmaceuticals International GmbH et al. v. Eli Lilly and Company, C.A. No. 18-12029-ADB (D. Mass.). Represented Teva in high-stakes patent litigation involving method-of-treatment patents directed to anti-CGRP biologic therapies, including Eli Lilly’s Emgality® (galcanezumab) product
• Certain Pre-Filled Syringes for Intravitreal Injection and Components Thereof, Inv. No. 337-TA-1207 (USITC); Novartis Pharma AG et al v. Regeneron Pharmaceuticals, Inc., C.A. No. 20-00690-DNH (N.D.N.Y.); Regeneron Pharmaceuticals, Inc. v. Novartis Pharma AG, et al., IPR2020-01317, IPR2020-01318, IPR2021-00816 (P.T.A.B.). Represented Novartis in parallel ITC investigations, distinct court litigations, and inter partes review proceedings involving Novartis’s pre-filled syringe technology for intravitreal injection, including Regeneron’s EYLEA® (aflibercept) product
• Par Pharmaceutical et al. v. Amneal et al., C.A. No. 18-2032-CFC (D. Del.). Represented Amneal Pharmaceuticals in patent infringement case involving a generic formulation of Vasostrict® (vasopressin) injection
• Various non-public representations involving complex pharmaceutical intellectual property, licensing, and trade secret disputes

Zachariah joined Goodwin in 2019 as a science advisor before becoming an associate in the firm’s Intellectual Property Litigation practice. Prior to his legal career, he earned a PhD in Biochemistry from the University of Colorado, where his research focused on biophysical characterization of proteins involved in stem cell pluripotency. His scientific work also included development of RNA-based live-cell imaging technique and the investigation of several RNA-based mechanisms of gene regulation.

Zachariah is a member of the Massachusetts LGBTQ Bar Association, the Massachusetts Bar Association, and Out in IP.

Zachariah was awarded the Leo J. Wyman Award by the faculty of Suffolk University Law School as well as the Rehnquist Award for Excellence in Professional Responsibility.

Zachariah has published scientific articles in peer-reviewed journals, including Nature Chemical Biology, Nature Communications and Nucleic Acids Research. He is an editor of Big Molecule Watch, Goodwin’s blog covering legal, business and regulatory developments involving biologics, biosimilars and the Biologics Price Competition and Innovation Act (BPCIA).

• Webinar, “So You Want to Make a Biosimilar – Top Considerations Before BLA Submission,” March 2026
• Webinar, “Unpacking the Vaccine Patent Battles: What Every Life Sciences Team Needs to Know,” January 2026
• Webinar, “The Fate of the Therapeutic Dosing Regimen: Trends and Considerations in Validity Challenges to Dosing Patent Claims,” March 2024
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024 ed.,” Thomson Reuters, January 2024
• Contributor, “Guide to Biosimilars Litigation and Regulation in the U.S., 2019-2020 ed.,” Thomson Reuters, November 2019